GlassScriptPhysician profile
Abraham S Chen
NPI 1942488101
$17,489.68
in general payments reported to CMS, 2019-2025
58 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,061 · 2020: $2,643 · 2021: $5,476 · 2022: $4,000 · 2023: $2,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,309.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,898.97 | 2019-2023 | Farxiga, Breztri |
| Biohaven Pharmaceuticals, INC. | $1,786.22 | 2020-2021 | |
| Abbvie INC. | $1,521.48 | 2019-2023 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $965.71 | 2019-2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $814.69 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $787.56 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $654.53 | 2019-2023 | |
| Lilly USA, LLC | $624.37 | 2019-2023 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $603.65 | 2019-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $541.21 | 2019-2023 | Trintellix |
| Antares Pharma, INC. | $529.64 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $516.74 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $497.22 | 2019-2022 | |
| Allergan, INC. | $485.74 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $452.18 | 2019-2021 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.